Novo Nordisk’s anti-obesity drug reduced people’s risk of suffering heart attacks, strokes and cardiovascular deaths by 20%.
Source link
Tags: Cardiovascular Conditions, community, Diabetes, Diabetes Drugs, drink, episodic, Episodic/Paroxysmal Disorders, Food, Food/Drink, general news, Health, healthcare, Healthcare/Life Sciences, Hormone Products, life sciences, lifestyle, living, Living/Lifestyle, Medical Conditions, medications, Nutrition, Obesity, paroxysmal disorders, Pharmaceuticals, political, Political/General News, Sleep Disorders, Social issues, society, Society/Community, specialized drugs, Specialized Drugs/Medications, Stroke, SYND, WSJ-PRO-WSJ.com, wsjhealth
